The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate &bgr；-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.La invenciones refiere a anticuerpos anti R-espondina 3 humana (RSPO3) que inhiben la unión de RSPO3 a un receptor acoplado a proteína G. Una composición farmacéutica que lo comprende y sus usos para fabricar un medicamento útil para inhibir el crecimiento de tumor.
